Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial

Alfred Callahan, Pierre Amarenco, Larry B Goldstein, Henrik Sillesen, Mike Messig, Gregory P Samsa, Irfan Altafullah, Lucy Y Ledbetter, Mary J MacLeod, Russell Scott, Michael Hennerici, Justin A Zivin, K Michael A Welch, SPARCL Investigators

Research output: Contribution to journalArticle

67 Citations (Scopus)

Abstract

To perform a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial, which tested the effect of treatment with atorvastatin in reducing stroke in subjects with a recent stroke or transient ischemic attack, to explore the effects of treatment in subjects with type 2 diabetes mellitus or metabolic syndrome (MetS).
Original languageEnglish
Pages (from-to)1245-1251
Number of pages7
JournalArchives of Neurology
Volume68
Issue number10
DOIs
Publication statusPublished - 2011

Keywords

  • Adult
  • Aged
  • Aged, 80 and over
  • Cardiovascular Physiological Processes
  • Cholesterol
  • Confidence Intervals
  • Diabetes Mellitus, Type 2
  • Female
  • Heptanoic Acids
  • Humans
  • Hydroxymethylglutaryl-CoA Reductase Inhibitors
  • Ischemic Attack, Transient
  • Lipoproteins, HDL
  • Lipoproteins, LDL
  • Male
  • Metabolic Syndrome X
  • Middle Aged
  • Proportional Hazards Models
  • Pyrroles
  • Retrospective Studies
  • Risk Factors
  • Stroke
  • Triglycerides
  • Young Adult

Fingerprint Dive into the research topics of 'Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial'. Together they form a unique fingerprint.

  • Cite this

    Callahan, A., Amarenco, P., Goldstein, L. B., Sillesen, H., Messig, M., Samsa, G. P., Altafullah, I., Ledbetter, L. Y., MacLeod, M. J., Scott, R., Hennerici, M., Zivin, J. A., Welch, K. M. A., & SPARCL Investigators (2011). Risk of stroke and cardiovascular events after ischemic stroke or transient ischemic attack in patients with type 2 diabetes or metabolic syndrome: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Archives of Neurology, 68(10), 1245-1251. https://doi.org/10.1001/archneurol.2011.146